

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>( Not for submission under 37 CFR 1.99)</i>	Application Number		10547207
	Filing Date		2005-08-26
	First Named Inventor		Paul Andrew Hamblin
	Art Unit		1609
	Examiner Name		Meera Natarajan
	Attorney Docket Number		VB60033

U.S.PATENTS						<input type="button" value="Remove"/>
Examiner Initial*	Cite No	Patent Number	Kind Code†	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	5989552	A	1999-11-23	McKenzie	
	2	6177256	B1	2001-01-23	McKenzie	
	3	6548643	B1	2003-04-15	McKenzie	

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						<input type="button" value="Remove"/>
Examiner Initial*	Cite No	Publication Number	Kind Code†	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20060062798	A1	2006-03-23	Burden et al.	
	2	20060251665	A1	2006-11-09	Burden et al.	
	3	20070042047	A1	2007-02-22	Hamblin et al.	

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10547207
Filing Date	2005-06-26
First Named Inventor	Paul Andrew Hamblin
Art Unit	1609
Examiner Name	Meera Natarajan
Attorney Docket Number	VB60033

	4	20030133909	A1	2003-07-17	Crowe et al.	
--	---	-------------	----	------------	--------------	--

If you wish to add additional U.S. Published Application citation information please click the Add button

**FOREIGN PATENT DOCUMENTS**

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> i	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1	0157068	WO	A1	2001-08-09	The Austin Research Institute		<input type="checkbox"/>
	2	0006723	WO	A1	2000-02-10	Yeda Research and Development Company Ltd at the W		<input type="checkbox"/>
	3	0118035	WO	A2	2001-03-15	Transgene S.A.		<input type="checkbox"/>
	4	95018145	WO	A1	1995-07-06	The Austin Research Institute		<input type="checkbox"/>
	5	97011715	WO	A1	1997-04-03	The Austin Research Institute		<input type="checkbox"/>
	6	9940881	WO	A2	1999-08-19	Bastert, Gunther		<input type="checkbox"/>
	7	0146228	WO	A2	2001-06-28	Glaxo Group Limited		<input type="checkbox"/>
	8	0220598	WO	A1	2002-03-14	McGuckin, Michael Andrew; Williams, Stephanie Jane		<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10547207
Filing Date	2005-06-26
First Named Inventor	Paul Andrew Hamblin
Art Unit	1609
Examiner Name	Meera Natarajan
Attorney Docket Number	VB60033

	9	03031569	WO	A2	2003-04-17	Centocor, Inc.		<input type="checkbox"/>
	10	05051991	WO	A2	2005-06-09	Sidney Kimmel Cancer Center		<input type="checkbox"/>
	11	05058950	WO	A2	2005-06-30	Sidney Kimmel Cancer Center		<input type="checkbox"/>
	12	2005058937	WO	A2	2005-06-30	Government of the United States of America, as rep		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

Add

**NON-PATENT LITERATURE DOCUMENTS**

Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	Ts
	1	FONG AND HUI; Generation of potent and specific cellular immune responses via in vivo stimulation of dendritic cells by pNGVL3-hFlex plasmid DNA and immunogenic peptides; Gene Therapy; 2002; 9; 1127-1138;	<input type="checkbox"/>
	2	JOHNEN ET A; Long-term tumor growth suppression in mice immunized with naked DNA of the human tumor antigen mucin (MUC1); Cancer Immunology and Immunotherapy; 2001; 50; 356-360;	<input type="checkbox"/>
	3	KAMATA ET AL; Vaccination of mice with MUC1 cDNA suppresses the development of lung metastases; Clinical and Experimental Metastasis; 2002; 19; 689-696;	<input type="checkbox"/>
	4	KONTANI ET AL., Novel vaccination protocol consisting of injecting MUC1 DNA and nonprimed dendritic cells at the same region greatly enhanced MUC1-specific antitumor immunity in a murine model, Cancer Gene Therapy, 2002, 9, 330-337,	<input type="checkbox"/>
	5	PECHER AND FINN; Induction of cellular immunity in chimpanzees to human tumor-associated antigen mucin by vaccination with MUC-1 cDNA-transfected Epstein-Barr virus-immortalized autologous B cells; Proceedings of the National Academy of Science USA; 1996; 93; 1699-1704;	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10547207
Filing Date	2005-06-26
First Named Inventor	Paul Andrew Hamblin
Art Unit	1609
Examiner Name	Meera Natarajan
Attorney Docket Number	VB60033

6	ROCHLITZ ET AL; Phase 1 immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer; <i>The Journal of Gene Medicine</i> ; 2003; 5; 690-699.	<input type="checkbox"/>
7	SCHOLL ET AL; Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer; <i>Journal of Immunotherapy</i> ; 2000; 23/5; 570-580.	<input type="checkbox"/>
8	VASILEVKO ET AL; Immunization with a vaccine that combines the expression of MUC1 and B7 co-stimulatory molecules prolongs the survival of mice and delays the appearance of mouse mammary tumors; <i>Clinical and Experimental Metastasis</i> ; 2003; 20; 489-496;	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>4</sup> Kind of document by the appropriate symbol as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10547207
Filing Date	2005-06-26
First Named Inventor	Paul Andrew Hamblin
Art Unit	1609
Examiner Name	Meera Natarajan
Attorney Docket Number	VB60033

**CERTIFICATION STATEMENT**

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

**OR**

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

None

**SIGNATURE**

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	Virginia G. Campen/	Date (YYYY-MM-DD)	2007-08-02
Name/Print	Virginia G. Campen	Registration Number	37,092

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 216(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.